Go Pro
→ The case for $20,000 gold before year end (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AxoGen, Inc. stock logo
AXGN
AxoGen
$41.99
-1.1%		$45.93
$15.27
▼
$52.91
$2.25B1.161.11 million shs428,062 shs
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$15.92
+0.4%		$15.49
$8.12
▼
$17.42
$552.06M0.57470,586 shs102,960 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$33.04
+3.9%		$33.64
$25.77
▼
$43.15
$3.85B0.693.05 million shs4.61 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AxoGen, Inc. stock logo
AXGN
AxoGen
-2.12%-4.71%-17.54%-3.59%+145.89%
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
+0.25%-3.35%-3.00%+22.77%+45.41%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-3.69%-22.13%-1.09%-15.13%+23.25%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AxoGen, Inc. stock logo
AXGN
AxoGen
$41.99
-1.1%		$45.93
$15.27
▼
$52.91
$2.25B1.161.11 million shs428,062 shs
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$15.92
+0.4%		$15.49
$8.12
▼
$17.42
$552.06M0.57470,586 shs102,960 shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$33.04
+3.9%		$33.64
$25.77
▼
$43.15
$3.85B0.693.05 million shs4.61 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AxoGen, Inc. stock logo
AXGN
AxoGen
-2.12%-4.71%-17.54%-3.59%+145.89%
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
+0.25%-3.35%-3.00%+22.77%+45.41%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-3.69%-22.13%-1.09%-15.13%+23.25%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AxoGen, Inc. stock logo
AXGN
AxoGen
2.69
Moderate Buy$52.1123.63% Upside
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
3.00
Buy$23.1745.61% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
2.75
Moderate Buy$99.67203.08% Upside

Current Analyst Ratings Breakdown

Latest DCTH, VKTX, and AXGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/29/2026
AxoGen, Inc. stock logo
AXGN
AxoGen
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold
9/28/2026
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D+) ➝ Hold (C-)
9/25/2026
AxoGen, Inc. stock logo
AXGN
AxoGen
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$48.00 ➝ $53.00
9/23/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$83.00 ➝ $87.00
9/22/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$120.00
9/22/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/22/2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/4/2026
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Sell (D+)
8/26/2026
AxoGen, Inc. stock logo
AXGN
AxoGen
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/26/2026
AxoGen, Inc. stock logo
AXGN
AxoGen
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$60.00
8/21/2026
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D+) ➝ Sell (D)
(Data available from 9/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AxoGen, Inc. stock logo
AXGN
AxoGen
$225.21M10.06N/AN/A$2.79 per share15.11
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$95.42M5.79$0.05 per share302.44$3.15 per share5.05
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$5.65 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AxoGen, Inc. stock logo
AXGN
AxoGen
-$15.70M-$0.68N/A468.34N/A-13.36%-8.90%-6.47%11/4/2026 (Estimated)
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
$2.70M$0.011,595.60132.58N/A0.56%0.46%0.42%11/3/2026 (Estimated)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$359.64M-$4.66N/AN/AN/AN/A-94.56%-82.75%10/28/2026 (Estimated)

Latest DCTH, VKTX, and AXGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/28/2026Q3 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.07N/AN/AN/AN/AN/A
8/6/2026Q2 2026
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
-$0.0891$0.07+$0.1591$0.07$26.25 million$29.13 million
7/29/2026Q2 2026
AxoGen, Inc. stock logo
AXGN
AxoGen
$0.1214$0.12-$0.0014-$0.03$67.10 million$69.73 million
7/29/2026Q2 2026
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$1.21-$1.10+$0.11-$1.10N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AxoGen, Inc. stock logo
AXGN
AxoGen
N/AN/AN/AN/AN/A
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
N/AN/AN/AN/AN/A
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AxoGen, Inc. stock logo
AXGN
AxoGen
0.07
6.60
5.04
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
N/A
9.83
8.95
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
4.72
4.72

Institutional Ownership

CompanyInstitutional Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
80.29%
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
61.12%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%

Insider Ownership

CompanyInsider Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
2.44%
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
19.36%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
5.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
AxoGen, Inc. stock logo
AXGN
AxoGen
62253.76 million52.45 millionOptionable
Delcath Systems, Inc. stock logo
DCTH
Delcath Systems
15634.70 million27.98 millionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
65116.65 million110.47 millionOptionable

Recent News About These Companies

Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.
September 29 at 6:22 PM  |  fool.comhttps://www.fool.com/investing/2026/09/29/eli-lilly-stock-barely-moved-following-viking-ther/
3 Non-AI Growth Stocks That Have Massive Upside
September 29 at 1:21 PM  |  fool.comhttps://www.fool.com/investing/2026/09/29/3-non-ai-growth-stocks-that-have-massive-upside/
VKTX Stock Logs 3-Day Losing Streak As $548M Raise Closes — Retail Calls Dip An ‘Easy Buy’ Amid Buyout Talks
September 29 at 3:20 AM  |  stocktwits.comS
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase ...
September 28 at 5:17 PM  |  markets.ft.comhttps://markets.ft.com/data/announce/detail?dockey=600-202609281630PR_NEWS_USPRX____LA58434-1
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
September 28 at 5:17 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/viking-therapeutics-announces-closing-concurrent-203000029.html
Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
September 28 at 4:30 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/viking-therapeutics-announces-closing-of-concurrent-upsized-offerings-of-common-stock-and-convertible-senior-notes-including-full-exercise-of-underwriters-options-to-purchase-additional-shares-of-common-stock-and-convertible-sen-302891919.html
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
September 28 at 12:16 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-think-viking-123002734.html
Viking Therapeutics Adds Weight Loss Maintenance As Potential New Growth Driver
September 28 at 11:56 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4950302-viking-therapeutics-adds-weight-loss-maintenance-potential-new-growth-driver
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm
September 28 at 11:12 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-viking-therapeutics-inc-to-contact-law-firm-302891041.html
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
September 28 at 10:31 AM  |  zacks.comhttps://www.zacks.com/stock/news/2996571/wall-street-analysts-think-viking-therapeutics-vktx-is-a-good-investment-is-it?cid=cs-stocknewsapi-ft-fundamental_analysis|average_broker_rating-2996571
Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution
September 27 at 12:43 PM  |  fool.comhttps://www.fool.com/investing/2026/09/27/viking-therapeutics-delivers-great-vk2735-results/
3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzing
September 27 at 4:55 AM  |  fool.comhttps://www.fool.com/investing/2026/09/27/numbers-viking-therapeutics-weight-loss-drug/
Viking Therapeutics Stock Falls 15% After $483 Mln Equity And Convertible Notes Offering
September 26, 2026  |  rttnews.comhttps://www.rttnews.com/3693742/viking-therapeutics-stock-falls-15-after-483-mln-equity-and-convertible-notes-offering.aspx
Is Viking Therapeutics, Inc. (VKTX) the Healthcare Stocks Stock Everyone's About to Talk About?
September 26, 2026  |  kalkinemedia.comK
Bronze bull and bear statues face off in an urban financial district at sunset.
MarketBeat Week in Review – 09/21 - 09/25 (VKTX)
...
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/articles/marketbeat-week-in-review-09-21-09-25/
Viking Therapeutics, Inc. $VKTX Shares Newly Acquired by Bank of America Corp DE
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-viking-therapeutics-inc-vktx-shares-newly-acquired-by-bank-of-america-corp-de-2026-09-26/
Viking Therapeutics (NASDAQ:VKTX) Stock Bumped Up to "Sell" by Wall Street Zen
September 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31051374
Viking Therapeutics (NASDAQ:VKTX) Stock Rating Raised to Sell at Wall Street Zen
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-viking-therapeutics-nasdaq-vktx-stock-rating-raised-to-sell-at-wall-street-zen-2026-09-26/
Is Viking Therapeutics (VKTX) Getting Too Rich After VK2735 Data?
September 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/viking-therapeutics-vktx-getting-too-190916054.html
Latham Advises on Viking Therapeutics’ Upsized US$500 Million Offering of Common Stock and Convertible Senior Notes
September 25, 2026  |  legaldesire.comL
Viking Therapeutics (NASDAQ:VKTX) Sees Strong Trading Volume - Time to Buy?
September 25, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31048976

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Viking Therapeutics logo displayed among laboratory glassware, a vial, and a syringe in a lab setting.
Viking's Obesity Edge May Be Staying Power, Not Weight Loss
By Chris Markoch | September 23, 2026
Laboratory workstation with a centrifuge, pipettes, sample racks, and automated liquid-handling equipment on a metal bench.
3 Emerging Biotech Stocks With Significant Upside Potential
By Thomas Hughes | September 30, 2026
AxoGen stock logo

AxoGen NASDAQ:AXGN

$41.98 -0.46 (-1.07%)
As of 02:07 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

Delcath Systems stock logo

Delcath Systems NASDAQ:DCTH

$15.92 +0.07 (+0.44%)
As of 02:06 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$33.03 +1.23 (+3.85%)
As of 02:07 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas